MAPT and Alzheimer disease: To further examine the study’s hypotheses among individuals with significant evidence of AD pathophysiological process, we identified 68 participants among all Aβ + participants, who were CSF tau positive (p-tau ≥23 pg/ml (Shaw et al. 2009)) and entered them into the same analyses.